The Nyxoah Genio™ system is a device to treat people with obstructive sleep apnoea (OSA) who are not suitable for continuous positive airway pressure (CPAP) therapy. OSA is a common sleep disorder where the walls of the throat relax and narrow during sleep, interrupting normal breathing. The Nyxoah Genio™ system consists of a device which is implanted under the chin, and a disposable patch with an activation chip which is worn on the chin every night. The patch wirelessly stimulates the nerves of the tongue to make it contract and prevent obstruction of the airway. The activation chip is removed every morning and recharged. The developer says the advantage of the device is that it can be easily implanted, that it is discreet and could improve quality of life and compliance for people with OSA.
Nintedanib is already licensed for treating idiopathic pulmonary fibrosis which is a subtype of ILDs. Nintedanib acts by blocking specific enzymes and pathways that lead to the development of blood vessels within lung cells involved in the scarring process. This inhibits further growth of the scarring tissues resulting in slowing of the disease progression. This action has been shown to be similar in patients with idiopathic pulmonary fibrosis. If licensed, nintedanib may provide the first novel therapy for PF-ILD where limited treatment options currently exist.